Anders Ingvarsson, board member of AegirBio AB (“AegirBio” or the “Company”) since 2019, has announced his intention to resign as board member and chairman of AegirBio. The reason for the decision is personal reasons.

Anders Ingvarsson will leave the board in connection with the extraordinary general meeting that the board intends to convene shortly, in accordance with the press release published earlier today. Notice of the extraordinary general meeting will be published in a separate press release.

“I am pleased to note that the financing solution we have developed will facilitate the conditions for AegirBio to continue with the RADx® Tech program. It has been a great honor for me to lead the work of the board, and to work with the management and all employees. I am proud of what we have achieved and look forward to following the Company’s continued development from outside the boardroom”, says Anders Ingvarsson, Chairman of the Board of AegirBio.

This disclosure contains information that AegirBio is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-04-2024 08:45 CET.

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB; adviser@eminova.sE

Related link:
Cision